A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains
- PMID: 28266614
- PMCID: PMC5339694
- DOI: 10.1038/srep43238
A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains
Abstract
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of conditions that include steatohepatitis and fibrosis that are thought to emanate from hepatic steatosis. Few robust biomarkers or diagnostic tests have been developed for hepatic steatosis in the setting of obesity. We have developed a multi-component classifier for hepatic steatosis comprised of phenotypic, genomic, and proteomic variables using data from 576 adults with extreme obesity who underwent bariatric surgery and intra-operative liver biopsy. Using a 443 patient training set, protein biomarker discovery was performed using the highly multiplexed SOMAscan® proteomic assay, a set of 19 clinical variables, and the steatosis predisposing PNPLA3 rs738409 single nucleotide polymorphism genotype status. The most stable markers were selected using a stability selection algorithm with a L1-regularized logistic regression kernel and were then fitted with logistic regression models to classify steatosis, that were then tested against a 133 sample blinded verification set. The highest area under the ROC curve (AUC) for steatosis of PNPLA3 rs738409 genotype, 8 proteins, or 19 phenotypic variables was 0.913, whereas the final classifier that included variables from all three domains had an AUC of 0.935. These data indicate that multi-domain modeling has better predictive power than comprehensive analysis of variables from a single domain.
Conflict of interest statement
The authors declare no competing financial interests.
Figures



Similar articles
-
[Study of the role of biomarkers in determining the course of non-alcoholic fatty liver disease in children with obesity].Vopr Pitan. 2025;94(2):85-96. doi: 10.33029/0042-8833-2025-94-2-85-96. Epub 2025 Mar 17. Vopr Pitan. 2025. PMID: 40418137 Russian.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.Nutrients. 2022 Dec 9;14(24):5261. doi: 10.3390/nu14245261. Nutrients. 2022. PMID: 36558421 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Non-invasive diagnostic tests for Helicobacter pylori infection.Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD012080. doi: 10.1002/14651858.CD012080.pub2. Cochrane Database Syst Rev. 2018. PMID: 29543326 Free PMC article.
Cited by
-
Label-Free Proteomics of Severe Acute Hepatitis of Unknown Origin in Children by High-Resolution Mass Spectrometry.ACS Omega. 2024 Dec 13;9(51):50685-50694. doi: 10.1021/acsomega.4c08745. eCollection 2024 Dec 24. ACS Omega. 2024. PMID: 39741806 Free PMC article.
-
Multidimensional landscape of non-alcoholic fatty liver disease-related disease spectrum uncovered by big omics data: Profiling evidence and new perspectives.Smart Med. 2023 Apr 17;2(2):e20220029. doi: 10.1002/SMMD.20220029. eCollection 2023 May. Smart Med. 2023. PMID: 39188279 Free PMC article. Review.
-
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease.Metabolism. 2020 Oct;111S:154320. doi: 10.1016/j.metabol.2020.154320. Epub 2020 Jul 23. Metabolism. 2020. PMID: 32712221 Free PMC article. Review.
-
Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.Metabolites. 2023 Oct 29;13(11):1115. doi: 10.3390/metabo13111115. Metabolites. 2023. PMID: 37999211 Free PMC article. Review.
-
Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment.Gut. 2025 Jan 17;74(2):295-311. doi: 10.1136/gutjnl-2023-331740. Gut. 2025. PMID: 39174307 Free PMC article. Review.
References
-
- Chalasani N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005–2023, doi: 10.1002/hep.25762 (2012). - DOI - PubMed
-
- Matteoni C. A. et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413–1419 (1999). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical